ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Clinical Report

The Many Faces of Solitary and Multiple Erythema Migrans

doi: 10.2340/00015555-1549

Abstract:

Case definitions for European Lyme disease have been published. However, multiple erythema migrans may pose a diagnostic challenge. Therefore, we retrospectively reviewed the clinical and serological findings and response to therapy in a cohort of consecutive 54 patients with PCR-confirmed erythema migrans, referred to a university dermatology clinic. The proportion of patients with multiple erythema migrans lesions (usually 2 or 3) was almost equal (46%) to the proportion of patients with single erythema migrans lesions (54%). All patients, except for 2 multiple erythema migrans patients with a concomitant autoimmune disease, completely responded to treatment. In conclusion, multiple erythema migrans may be more common than anticipated, and since only 50% of the patients were seropositive when seeking medi-cal help, PCR testing of skin lesions is helpful to confirm the diagnosis in clinically atypical cases.

Authors:

Pernilla Eriksson, Marika T. Schröder, Kirsi Niiranen, Antti Nevanlinna, Jaana Panelius, Annamari Ranki
Department of Dermatology and Allergology, Helsinki University Central Hospital, FIN-00029 HUS, Finland. E-mail: pernilla.eriksson@fimnet.fi

References

1. Hubalek Z. Epidemiology of lyme borreliosis. Curr Probl Dermatol 2009; 37: 31–50.

2. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69–79.

3. Hulkko T, Lyytikäinen O, Jaakola S, Kuusi M, Puumala J, Ruutu P. [Infectious diseases in Finland 2010]. [Report/webpage]. 2011; [accessed 2012 May 31]. Available from: http://www.thl.fi/thl-client/pdfs/1d73f597-8188-4ff5-b33c-101d7e1c3e90 (in Finnish).

4. Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringér A, Elmrud H, et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 1995; 333: 1319–1327.

5. Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F. Solitary and multiple erythema migrans in children: comparison of demographic, clinical and laboratory findings. Infection 2003; 31: 404–409.

6. Constantin C, Peter O, Cerottini J, Derighetti M, Panizzon R, Guggisberg D. Erythema migrans with multiple lesions. Ann Dermatol Venereol 2000; 127: 513–516.

7. Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B. Long-term prognosis of patients treated for erythema migrans in France. Br J Dermatol 2002; 146: 872–876.

8. Svihrova V, Hudeckova H, Jesenak M, Schwarzova K, Kostanova Z, Ciznar I. Lyme borreliosis – analysis of the trends in Slovakia, 1999–2008. Folia Microbiol (Praha) 2011; 56: 270–275.

9. Egberts F, Moller M, Proksch E, Schwarz T. Multiple erythema migrans – manifestation of systemic cutaneous borreliosis. J Dtsch Dermatol Ges 2008; 6: 350–353.

10. Åsbrink E, Hovmark A, Hederstedt B. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Derm Venereol 1984; 64: 506–512.

11. HUSLAB – Laboratory of Helsinki and Uusimaa Hospital District. Borrelia burgdorferi, vasta-aineet seerumista. [webpage]. 2012 [accessed 2012 May 31]. Available from: http://huslab.fi/cgi-bin/ohjekirja/tt_show.exe?assay=3552&terms=borrelia (in Finnish).

12. Ranki A, Aavik E, Peterson P, Schauman K, Nurmilaakso P. Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J Invest Dermatol 1994; 102: 339–345.

13. Current Care working group – Finnish Medical Society Duodecim and Finnish Dermatological Society. [Bacterial infections of the skin] [webpage]. 2010 [accessed 2012 May 31]. Available from: http://www.terveysportti.fi/xmedia/hoi/hoi13020.pdf (in Finnish).

14. Uggeldahl P, Peltomaa M. [Skin manifestations of Lyme borreliosis]. Duodecim 2010; 126: 1151–1161 (in Finnish).

15. EUCALB – European concerted action on Lyme borreliosis. Treatment of Lyme borreliosis in Europe. 2009 [accessed 2012 May 31]. Available from: http://meduni09.edis.at/eucalb/cms/index.php?option=com_content&task=view&id=44&Itemid=76.

16. Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, et al. A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol 2005; 12: 1069–1074.

17. Tjernberg I, Sillanpää H, Seppälä I, Eliasson I, Forsberg P, Lahdenne P. Antibody responses to borrelia IR(6) peptide variants and the C6 peptide in Swedish patients with ery­thema migrans. Int J Med Microbiol 2009; 299: 439–446.

18. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD,Jr, Philipp MT, Steere AC, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187: 1187–1199.

19. Peltomaa M, McHugh G, Steere AC. Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J Infect Dis 2003; 187: 1178–1186.

20. Sillanpää H, Lahdenne P, Sarvas H, Arnez M, Steere A, Peltomaa M, et al. Immune responses to borrelial VlsE IR6 peptide variants. Int J Med Microbiol 2007; 297: 45–52.

21. Marangoni A, Moroni A, Accardo S, Cevenini R. Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 2008; 27: 349–354.

22. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089–1134.

23. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379: 461–473.

24. Yrjänäinen H, Hytönen J, Hartiala P, Oksi J, Viljanen MK. Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS 2010; 118: 665–673.

25. Klempner M, Hu L, Evans J, Schmid C, Johnson G, Trevino R, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85–92.

26. Sapi E, Kaur N, Anyanwu S, Luecke D, Datar A, Patel S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist 2011; 4: 97–113.

27. Embers M, Barthold S, Borda J, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 2012; 7: e29914.

28. Ziemer M, Grabner T, Eisendle K, Baltaci M, Zelger B. Granuloma annulare – a manifestation of infection with Borrelia? J Cutan Pathol 2008; 35: 1050–1057.

29. Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G Ital Dermatol Venereol 2009; 114: 157–171.

30. Zollinger T, Mertz K, Schmid M, Schmitt A, Pfaltz M, Kempf W. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J Cutan Pathol 2010; 37: 571–577.

31. Sjöwall J, Fryland L, Nordberg M, Sjögren F, Garpmo U, Jansson C, et al. Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans. PLoS One 2011; 6: e18220.

32. Strle F, Nelson JA, Ruzic-Sabljic E, Cimperman J, Maraspin V, Lotric-Furlan S, et al. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis 1996; 23: 61–65.

33. Oksi J, Marttila H, Soini H, Aho H, Uksila J, Viljanen MK. Early dissemination of Borrelia burgdorferi without generalized symptoms in patients with erythema migrans. APMIS 2001; 109: 581–588.

34. Strle F, Videcnik J, Zorman P, Cimperman J, Lotric-Furlan S, Maraspin V. Clinical and epidemiological findings for patients with erythema migrans. Comparison of cohorts from the years 1993 and 2000. Wien Klin Wochenschr 2002; 114: 493–497.

35. Nadelman RB, Nowakowski J, Forseter G, Goldberg NS, Bittker S, Cooper D, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100: 502–508.

36. Brettschneider S, Bruckbauer H, Klugbauer N, Hofmann H. Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis. J Clin Microbiol 1998; 36: 2658–2665.

37. Subak S. Effects of climate on variability in Lyme disease incidence in the northeastern United States. Am J Epidemiol 2003; 157: 531–538.

Related articles

There are no related articles.


Share with your friends





Actions


Abstract

Full text

PDF

Supplementary


There is no supplementary for this article.

Print information


Volume 93, Issue 6

DOI: 10.2340/00015555-1549

Pages: 693-700

View at PubMed